Literature DB >> 21741629

Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion.

Andrew J Russ1, Kyle Xu, Lucy Wentworth, Sheeba Alam, Justin V Meyers, Michael D Macklin, Alexander L Rakhmilevich, Victoria Rajamanickam, M Suresh, Clifford S Cho.   

Abstract

We have observed that in vivo interaction between melanoma and resting T cells promotes suppression of antigen-driven proliferative T cell expansion. We hypothesized that this suppression would affect tumor antigen-specific T cell populations more potently than tumor-unrelated T cell populations. A B16F10 cell line was stably transfected to express low levels of the lymphocytic choriomeningitis virus (LCMV) glycoprotein GP33 (B16GP33). Mice bearing B16F10 or B16GP33 tumors were infected with LCMV, and proliferative expansion of LCMV epitope-specific T cell populations was quantified. In vitro and in vivo assays confirmed low levels of antigenic GP33 expression by B16GP33 tumors. Suppressed expansion of GP33-specific T cells was equivalent between mice bearing B16F10 and B16GP33 tumors. These observations suggest that the ability of growing melanoma tumors to impair antigen-driven proliferative expansion of activated T cells is global and not antigen-specific, and provide further insight into the influence of cancer on activated T cell homeostasis. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741629      PMCID: PMC4852956          DOI: 10.1016/j.cellimm.2011.06.011

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  15 in total

1.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Suppression of T-cell expansion by melanoma is exerted on resting cells.

Authors:  Andrew J Russ; Lucy Wentworth; Kyle Xu; Alexander Rakhmilevich; Christine M Seroogy; Paul M Sondel; M Suresh; Clifford S Cho
Journal:  Ann Surg Oncol       Date:  2011-04-05       Impact factor: 5.344

3.  The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules.

Authors:  D Hudrisier; M B Oldstone; J E Gairin
Journal:  Virology       Date:  1997-07-21       Impact factor: 3.616

Review 4.  Cancer immunoediting from immune surveillance to immune escape.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe
Journal:  Immunology       Date:  2007-03-26       Impact factor: 7.397

Review 5.  Less yin, more yang: confronting the barriers to cancer immunotherapy.

Authors:  Gregory Lizée; Mayra A Cantu; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

7.  Adaptive immunity maintains occult cancer in an equilibrium state.

Authors:  Catherine M Koebel; William Vermi; Jeremy B Swann; Nadeen Zerafa; Scott J Rodig; Lloyd J Old; Mark J Smyth; Robert D Schreiber
Journal:  Nature       Date:  2007-11-18       Impact factor: 49.962

Review 8.  Tumors as elusive targets of T-cell-based active immunotherapy.

Authors:  Francesco M Marincola; Ena Wang; Meenhard Herlyn; Barbara Seliger; Soldano Ferrone
Journal:  Trends Immunol       Date:  2003-06       Impact factor: 16.687

Review 9.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

Review 10.  Adoptive cell therapy for the treatment of patients with metastatic melanoma.

Authors:  Steven A Rosenberg; Mark E Dudley
Journal:  Curr Opin Immunol       Date:  2009-03-21       Impact factor: 7.486

View more
  9 in total

1.  Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Authors:  Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2016-03-24       Impact factor: 6.968

2.  Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.

Authors:  David A Mahvi; Justin V Meyers; Andrew J Tatar; Amanda Contreras; Marulasiddappa Suresh; Glen E Leverson; Siddhartha Sen; Clifford S Cho
Journal:  J Immunother       Date:  2015 Feb-Mar       Impact factor: 4.456

3.  Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.

Authors:  Miriam Alb; Christopher Sie; Christian Adam; Suzie Chen; Jürgen C Becker; David Schrama
Journal:  Cancer Immunol Immunother       Date:  2012-06-07       Impact factor: 6.968

4.  Memory T cells are uniquely resistant to melanoma-induced suppression.

Authors:  Lucy Wentworth; Justin V Meyers; Sheeba Alam; Andrew J Russ; M Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2012-08-04       Impact factor: 6.968

5.  Systemic dysfunction and plasticity of the immune macroenvironment in cancer models.

Authors:  Breanna M Allen; Kamir J Hiam; Cassandra E Burnett; Anthony Venida; Rachel DeBarge; Iliana Tenvooren; Diana M Marquez; Nam Woo Cho; Yaron Carmi; Matthew H Spitzer
Journal:  Nat Med       Date:  2020-05-25       Impact factor: 53.440

6.  Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model.

Authors:  Amanda Contreras; Megan V Beems; Andrew J Tatar; Siddhartha Sen; Prakrithi Srinand; M Suresh; Tahra K Luther; Clifford S Cho
Journal:  J Immunother Cancer       Date:  2018-05-29       Impact factor: 13.751

Review 7.  Systemic immunity in cancer.

Authors:  Kamir J Hiam-Galvez; Breanna M Allen; Matthew H Spitzer
Journal:  Nat Rev Cancer       Date:  2021-04-09       Impact factor: 60.716

8.  Japanese Kampo Medicine Juzentaihoto Improves Antiviral Cellular Immunity in Tumour-Bearing Hosts.

Authors:  Shun Takaku; Masumi Shimizu; Rimpei Morita
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-13       Impact factor: 2.650

9.  Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy.

Authors:  Shibin Qu; Tejaswi Worlikar; Amy E Felsted; Anutosh Ganguly; Megan V Beems; Ryan Hubbard; Ashley L Pepple; Alicia A Kevelin; Hannah Garavaglia; Joe Dib; Mariam Toma; Hai Huang; Allan Tsung; Zhen Xu; Clifford Suhyun Cho
Journal:  J Immunother Cancer       Date:  2020-01       Impact factor: 13.751

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.